Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

IMPACT-MACS: Adrenalectomía frente a Semaglutida para Resultados Metabólicos en la Secreción Cortisol Autónoma Leve (IMPACT-MACS)

15 de noviembre de 2026 actualizado por: Oksana Hamidi, DO, MSCS, University of Texas Southwestern Medical Center

Estudio IMPACT-MACS: Investigación de los Mecanismos, Fisiopatología y Tratamiento Cardiometabólico en la Secreción Autónoma Leve de Cortisol

The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn how these treatments impact body composition, blood pressure, cholesterol, inflammation, muscle strength, and quality of life.

The main questions the study aims to answer are:

  1. Does adrenalectomy or semaglutide improve insulin resistance more in people with MACS?
  2. How do these treatments change cortisol patterns and other cardiometabolic risk factors?
  3. Do people with MACS respond differently to semaglutide compared to matched adults without MACS?
  4. Among participants who enter the optional extension phase, are treatment-related changes maintained or further modified with longer-term treatment and follow-up?

Participants will:

  1. Receive either adrenalectomy or semaglutide if they have MACS, or semaglutide if they are matched controls
  2. Complete clinic visits and phone visits
  3. Undergo metabolic testing such as blood tests, urine steroid profiling, body composition scans, blood pressure monitoring, muscle strength testing, and questionnaires about health and well-being
  4. If eligible, have the option to participate in an extension phase with continued treatment and follow-up through approximately 12 months

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This single-center, prospective, interventional study evaluates metabolic responses to surgical versus medical treatment in adults with mild autonomous cortisol secretion (MACS). The study includes:

  1. a randomized controlled trial comparing adrenalectomy to semaglutide in MACS, and
  2. a parallel matched case-control comparison evaluating semaglutide effects in MACS versus matched controls without adrenal tumors.

The primary objective is to compare changes in insulin sensitivity measured by hyperinsulinemic-euglycemic clamp (M-value) from baseline to week 26. Secondary outcomes include cortisol dynamics, steroid profiling, cardiometabolic biomarkers, body composition, blood pressure, muscle strength, and patient-reported quality of life.

Semaglutide is administered within its FDA-approved indication for weight management; adrenalectomy is standard of care. No IND is required.

Participants who complete the initial 26-week study period and meet applicable eligibility criteria may elect to participate in an optional extension phase through approximately Week 52. During the extension phase, participants continue study follow-up and the intervention specified by the protocol, with additional assessments to evaluate longer-term changes in metabolic, hormonal, anthropometric, and cardiometabolic outcomes. Participation in the extension phase is voluntary and is not required for completion of the initial study period. The original primary outcome remains the change in insulin sensitivity from baseline to Week 26; assessments during the extension phase evaluate longer-term treatment effects and durability of response.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

75

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults ≥18 years
  • MACS groups: adrenal adenoma + DST cortisol >1.8 µg/dL + no overt Cushing + eligible for adrenalectomy
  • Willingness to postpone surgery 6 months if randomized
  • Controls: no adrenal abnormalities + normal DST + BMI ≥27 + ≥2 cardiometabolic conditions
  • Stable medication doses for ≥4 weeks
  • Negative pregnancy test if applicable

Exclusion Criteria:

  • Prior GLP-1 RA within 90 days
  • Weight change >5 kg in past 90 days
  • Prior obesity/diabetes surgery
  • Type 1 diabetes or other diabetes types
  • Severe organ disease
  • Recent pancreatitis
  • Pregnancy, breastfeeding
  • Contraindication to semaglutide
  • Contraindication to surgery delay
  • Chronic glucocorticoid use

Optional Extension Phase Eligibility:

Participants who complete the Core Study Period may participate in the Optional Extension Phase if they:

  • Successfully complete all Week 26 (Visit 8) assessments and procedures;
  • Remain compliant with study requirements;
  • Are considered by the Investigator to be appropriate for safe continued participation; and
  • Confirm their willingness to participate in the Optional Extension Phase.

For matched controls, the corresponding matched index participant must also elect to participate in the Optional Extension Phase and remain eligible for continued study participation.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Arm 1: Adrenalectomy (MACS)

Adults with mild autonomous cortisol secretion (MACS) who are clinically eligible for adrenalectomy undergo unilateral adrenalectomy as part of standard clinical care. Participants complete protocol-specified metabolic, hormonal, cardiometabolic, body composition, physical function, and patient-reported outcome assessments through Week 26. Eligible participants may elect to participate in the Optional Extension Phase, with continued follow-up and repeat outcome assessments through Month 12.

Surgical removal of one adrenal gland performed by an endocrine surgeon following institutional standard-of-care practices. Includes postoperative monitoring for adrenal insufficiency and routine clinical follow-up.

Comparador activo: Arm 2: Semaglutide (MACS)

Adults with MACS receive semaglutide during the initial 26-week treatment period. Eligible participants who elect to participate in the optional extension phase continue semaglutide treatment and protocol-specified follow-up through Month 12.

Once-weekly subcutaneous semaglutide administered according to FDA-approved titration for chronic weight management (0.25 mg to 2.4 mg weekly as tolerated). Participants receive training on injection technique, dose escalation, and safety monitoring.

Comparador activo: Arm 3: Semaglutide (Matched Controls)

Matched adults without adrenal tumors receive semaglutide using the same dosing approach as semaglutide-treated participants with MACS. This arm allows comparison of semaglutide responses between individuals with and without MACS. Eligible matched controls may participate in the Optional Extension Phase through Month 12 if their corresponding matched index participant also elects to participate and both remain eligible for continued study participation.

Once-weekly subcutaneous semaglutide administered according to FDA-approved titration for chronic weight management (0.25 mg to 2.4 mg weekly as tolerated). Participants receive training on injection technique, dose escalation, and safety monitoring.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Insulin Sensitivity (M-value), mg/kg/min
Periodo de tiempo: Baseline to Week 26

Hyperinsulinemic-euglycemic clamp

Baseline to Week 26

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in fasting plasma glucose, mg/dL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12
Baseline to Week 26; Baseline → Month 12
Change in hemoglobin A1C, %
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in fasting insulin, µU/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in glucagon, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in c-peptide, nmol/L
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in IGF-1, ng/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood glucose

Baseline to Week 26; Baseline → Month 12
Change in IGF-II, ng/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in IGFBP-1, ng/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in leptin, ng/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood glucose

Baseline to Week 26; Baseline → Month 12
Change in adiponectin, μg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
% of patients with normal dexamethasone suppression test, %
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

1-mg dexamethasone suppression test

Baseline to Week 26; Baseline → Month 12
Change in steroid profile, ng/24h
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

25-steroid profiling in the 24-hour urine, reported as aggregate

Baseline to Week 26; Baseline → Month 12
Mean change in systolic BP, mmHg
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

24-hour Ambulatory BP

Baseline to Week 26; Baseline → Month 12
Mean change in diastolic BP, mmHg
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

24-hour Ambulatory BP

Baseline to Week 26; Baseline → Month 12
Change in cholesterol, mg/dL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in Free Fatty Acids, mmol/L
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in C-reactive protein, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in TNF-alpha, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood glucose

Baseline to Week 26; Baseline → Month 12
Change in Interleukin-1, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in Interleukin-6, pg/mL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Fasting blood test

Baseline to Week 26; Baseline → Month 12
Change in body weight, kg
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

electronic scale

Baseline to Week 26; Baseline → Month 12
Change in BMI, kg/m2
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

calculated from weight and height

Baseline to Week 26; Baseline → Month 12
Change in waist circumference, cm
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Tape measure

Baseline to Week 26; Baseline → Month 12
Change in fat area, cm2
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Limited unenhanced CT

Baseline to Week 26; Baseline → Month 12
Change in muscle area, cm2
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Limited unenhanced CT

Baseline to Week 26; Baseline → Month 12
Change in bone mineral density, mg/cm³
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Limited unenhanced CT

Baseline to Week 26; Baseline → Month 12
Change in chair rise test, stands/30s
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Time test, number of stands from chair in 30 seconds

Baseline to Week 26; Baseline → Month 12
Change in Hand Grip Strength, kg
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Dynamometer

Baseline to Week 26; Baseline → Month 12
Change in overall quality of life, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

PROMIS Global Health Questionnaire, domain-specific scales;

The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health v1.2 Questionnaire assesses overall health-related quality of life across multiple domains, including physical health, mental health, social functioning, fatigue, and general well-being. It yields two standardized T-score summary measures (Global Physical Health and Global Mental Health).

Score Range: T-scores typically range from 20 to 80. Interpretation: Higher T-scores indicate better health-related quality of life. Assessment Method: Self-report questionnaire; estimated completion time 2-5 minutes.

Baseline to Week 26; Baseline → Month 12
Change in disease-specific QoL, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Cushing Quality of Life Questionnaire (CushingQoL)

Description:

The Cushing Quality of Life Questionnaire (CushingQoL) is a disease-specific tool assessing health-related quality of life in individuals with hypercortisolism. It contains 12 items scored on a 5-point Likert scale.

Score Range: 12 (minimum) to 60 (maximum). Interpretation: Higher scores indicate better quality of life; lower scores indicate poorer quality of life.

Domains: Sleep disturbances, mood, physical appearance, social interaction, health concerns.

Assessment Method: Self-administered; estimated completion time ~5 minutes.

Baseline to Week 26; Baseline → Month 12
Change in mood, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

PROMIS Depression Short Form & PROMIS Anxiety Short Form

Description:

The PROMIS Depression Short Form and PROMIS Anxiety Short Form measure depressive and anxiety symptoms over the past seven days, assessing emotional distress, negative affect, and somatic symptoms. Responses are on a 5-point Likert scale ("Never" to "Always"), converted to standardized T-scores.

Score Range: T-scores typically range from 20 to 80. Interpretation: Higher scores indicate worse depressive or anxiety symptoms. Assessment Method: Self-report questionnaires; estimated completion time 2-4 minutes each.

Baseline to Week 26; Baseline → Month 12
Change in cognition, seconds
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Trail Making Test - Part A and Part B (TMT-A and TMT-B)

Description:

The Trail Making Test Parts A and B assess visual attention, processing speed, cognitive flexibility, and executive function. Part A requires sequential connection of numbers; Part B requires alternating between numbers and letters.

Score Range: 0 to 300 seconds (maximum test time). Interpretation: Higher (longer) completion times indicate worse cognitive performance.

Assessment Method: Performance-based timed test administered by study personnel; expected duration ~5 minutes.

Baseline to Week 26; Baseline → Month 12
Change in sleep, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

PROMIS Sleep Disturbance Short Form

Description:

The PROMIS Sleep Disturbance Short Form evaluates sleep quality, difficulty initiating and maintaining sleep, and overall sleep problems over the past seven days. Scores are converted into standardized T-scores.

Score Range: T-scores typically range from 20 to 80. Interpretation: Higher scores indicate worse sleep disturbance. Assessment Method: Self-administered; estimated completion time 2-4 minutes.

Baseline to Week 26; Baseline → Month 12
Change in frailty, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

FRAIL Scale (Fatigue, Resistance, Ambulation, Illnesses, Loss of Weight)

Description:

The FRAIL Scale is a validated screening instrument assessing functional decline and physiological frailty. It consists of five yes/no items: fatigue, resistance, ambulation, illnesses, and weight loss.

Score Range: 0 (minimum) to 5 (maximum). Interpretation: Higher scores indicate greater frailty.

Frailty Categories:

0: Robust 1-2: Pre-frail 3-5: Frail

Assessment Method: Administered by study personnel; duration ~1 minute.

Baseline to Week 26; Baseline → Month 12
Change in eating behavior, score
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Eating Behavior and Appetite Questionnaire (EBAQ)

Description:

The Eating Behavior and Appetite Questionnaire (EBAQ) evaluates hunger, satiety, food cravings, and changes in appetite and eating behavior. It generates domain-specific and total scores.

Score Range: Varies by version; treated as continuous scores with defined minimum and maximum values per subscale.

Interpretation: Higher scores indicate greater appetite or more pronounced eating-behavior disturbances.

Assessment Method: Self-administered; estimated completion time 3-5 minutes.

Baseline to Week 26; Baseline → Month 12
Adverse Events and Serious Adverse Events
Periodo de tiempo: From assigned intervention through 4 weeks after the end of treatment, up to approximately Month 13 for participants entering the Optional Extension Phase.

AEs, SAEs

From assigned intervention through 4 weeks after the end of treatment, up to approximately Month 13 for participants entering the Optional Extension Phase.
Change in Insulin Sensitivity (M-value) at Month 12
Periodo de tiempo: Time Frame: Baseline to Month 12

Hyperinsulinemic-euglycemic clamp

Time Frame: Baseline to Month 12
Change in post-DST cortisol as a continuous variable
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

1-mg dexamethasone suppression test

Baseline to Week 26; Baseline → Month 12
Change in ACTH level
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
DHEA-S
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
HDL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
LDL
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
triglycerides
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
Apo B
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
Lp(a)
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
HDL function
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
cholesterol efflux capacity
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Blood test

Baseline to Week 26; Baseline → Month 12
Change in total fat area
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Body composition

Baseline to Week 26; Baseline → Month 12
Change in visceral fat area
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Body composition

Baseline to Week 26; Baseline → Month 12
Change in subcutaneous fat area
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Body composition

Baseline to Week 26; Baseline → Month 12
Change in muscle area
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Body composition

Baseline to Week 26; Baseline → Month 12
Change in muscle:fat ratio
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Body composition

Baseline to Week 26; Baseline → Month 12
Change in liver fat
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Body composition

Baseline to Week 26; Baseline → Month 12
Change in pancreatic fat
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Body composition

Baseline to Week 26; Baseline → Month 12
Change in pancreatic volume
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

Body composition

Baseline to Week 26; Baseline → Month 12
Change in adrenal nodule size
Periodo de tiempo: Baseline to Week 26; Baseline → Month 12

CT abdomen

Baseline to Week 26; Baseline → Month 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de marzo de 2026

Finalización primaria (Estimado)

31 de mayo de 2030

Finalización del estudio (Estimado)

31 de mayo de 2030

Fechas de registro del estudio

Enviado por primera vez

20 de enero de 2026

Primero enviado que cumplió con los criterios de control de calidad

21 de enero de 2026

Publicado por primera vez (Actual)

23 de enero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data (IPD) from the IMPACT-MACS study will be shared in accordance with NIH Data Management and Sharing Policy. Shared IPD will include primary and secondary outcome data such as insulin sensitivity (M-value), hormonal and cardiometabolic biomarkers, body composition measures, ambulatory blood pressure data, physical function tests, patient-reported outcomes, and adverse events. No genetic data will be shared. IPD will become available at the time of primary publication or by the end of the award period, expected by Q2 2030. Data will be accessible to qualified investigators for biomedical research through the NIDDK Central Repository, with requests managed under a Data Use Agreement. IRB approval or exemption is required, and data may not be used for ancestry or non-biomedical research.

Marco de tiempo para compartir IPD

Start Date:

Individual participant data (IPD) and supporting documents will become available at the time of primary results publication or by the end of the study award period, whichever occurs first. Availability is expected to begin by Q2 2030.

End Date:

IPD will remain available indefinitely through the NIDDK Central Repository, as long as the repository remains active and able to distribute the data under its Data Use Agreement procedures.

Criterios de acceso compartido de IPD

Individual participant data (IPD) and supporting materials will be available to qualified investigators conducting health-related, medical, or biomedical research. Requestors must submit a research proposal and obtain institutional IRB approval or exemption before access is granted.

Data will be shared in de-identified form through the NIDDK Central Repository, which manages requests under its governed Data Use Agreement (DUA) process. Approved investigators will be able to access the de-identified IPD, study protocol, and data dictionary through the repository's secure system. No identifiable information or genetic data will be shared.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .